1 completed, 1 recruiting, 1 unknown. 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Recruiting 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Skin Neoplasm: new trials by email Literature Review of Skin Neoplasm trials Research Report on Skin Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations Trastuzumab, Pertuzumab - Haematological Malignancy, Colorectal Neoplasms | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-03-07 | 2025-12-02 |
| Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance Pembrolizumab, Cetuximab - Skin Neoplasm | Phase 2 | Unknown | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 43 | 2018-10-01 | 2018-09-11 |
| A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma ASN-002, 5-FU - Basal Cell Nevus Syndrome, Skin Neoplasm | Phase 1 / Phase 2 | Completed | Ascend Biopharmaceuticals Ltd | 16 | 2015-09-01 | 2018-06-06 |
Skin Neoplasms (3) · Basal Cell Nevus Syndrome (1) · Colorectal Neoplasms (1) · Gallbladder Neoplasms (1) · Hematologic Neoplasms (1) · Lung Neoplasms (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Salivary Gland Neoplasms (1) · Urinary Bladder Neoplasms (1)
Neoplasms by Site (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Neoplasms (2) · Stomatognathic Diseases (2) · Abnormalities, Multiple (1) · Adnexal Diseases (1) · Biliary Tract Diseases (1) · Biliary Tract Neoplasms (1) · Bone Cysts (1) · Bone Diseases (1) · Bone Diseases, Developmental (1) · Carcinoma (1) · Carcinoma, Basal Cell (1) · Colonic Diseases (1)
Cetuximab (1) · Fluorouracil (1) · Trastuzumab (1) · gusacitinib (1) · pembrolizumab (1) · pertuzumab (1)
Ascend Biopharmaceuticals Ltd (1) · Cancer Research UK (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1)
Australia (1) · Italy (1) · United Kingdom (1)
Gregory Siller (1) · Lynda Spelman (1) · Matthew Krebs, Dr (1) · Paolo Bossi, MD (1) · Rodney Sinclair (1)